Skip to main content
Independent and nonpartisan. SaveYourState is a civic information resource. It is not a government website and is not affiliated with any government agency, party, or campaign.

California · 2025–26 Regular Session · Senate Bill

SB 1089: Preventive Treatment Health Care Act.

Enacted Official data

  1. Introduced
  2. In committee
  3. Passed one chamber
  4. Passed both chambers
  5. Enacted

Last official action: ·Record last updated:

Plain-language summary

SB 1089 is a senate bill introduced in the California Senate on February 13, 2026. According to its official title, it concerns: Preventive Treatment Health Care Act. Primary sponsor: Laura Richardson (D). It lists 1 additional sponsor. Most recent recorded action (September 28, 2026): Chaptered by Secretary of State. Chapter 725, Statutes of 2026.

Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written

Official summary

Legislative Counsel’s Digest (official, as of the latest version). Written by nonpartisan legislative staff; reproduced verbatim.

Existing law requires the California Health and Human Services Agency (CHHSA) to enter into partnerships resulting in the production of generic prescription drugs, including at least one form of insulin made available at production and dispensing costs, if one does not already exist in the market. Existing law additionally authorizes CHHSA to enter into partnerships to increase competition, lower prices, and address supply shortages for generic or brand name drugs to address emerging health concerns.

This bill, the Preventive Treatment Health Care Act, would authorize CHHSA to enter into partnerships, if needed and subject to an appropriation, to increase competition, lower prices, and address supply shortages for at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration (FDA). The bill would require CHHSA to establish distribution partners, if needed, and make its best effort to negotiate pricing at or lower than the cost to Medi-Cal beneficiaries in 2025.

Sponsors

Sponsors by party (alphabetical): Democratic 2

NameRolePartyChamberDistrict
Laura RichardsonPrimary sponsorDemocraticSenate35
Jessica CalozaCo-sponsorDemocraticAssembly52

“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.

Recent official actions

  1. Chaptered by Secretary of State. Chapter 725, Statutes of 2026.
  2. Chaptered by Secretary of State. Chapter 725, Statutes of 2026.
  3. Approved by the Governor.
  4. Approved by the Governor.
  5. Enrolled and presented to the Governor at 3 p.m.
  6. Enrolled and presented to the Governor at 3 p.m.
  7. Assembly amendments concurred in. (Ayes 40. Noes 0. Page 5987.) Ordered to engrossing and enrolling.
  8. Assembly amendments concurred in. (Ayes 39. Noes 0.) Ordered to engrossing and enrolling.
  9. Ordered to special consent calendar.
  10. Ordered to special consent calendar.
  11. In Senate. Concurrence in Assembly amendments pending.
  12. In Senate. Concurrence in Assembly amendments pending.

Sources

  1. California Legislative Information — pubinfo database export
  2. Official bill page